Company profile
Talphera, Inc.
NASDAQ: TLPH · Healthcare · Drug Manufacturers - Specialty & Generic
#1111 of 1,422 Healthcare companies by revenue
EA Score
46DFH 35DQ 65GM 40SS 51
v0.1 · 65/100 weight · provisional
↑ disclosure history, growth stability · ↓ operating margin, net margin
Methodology →Revenue TTM
$1.0k
Rev growth YoY (TTM)
-96.3%
Net income (FY)
-$14.3M
Employees
12
as of 2026-08-21
Market cap
$61.8M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$28.0k$28.0k2025
Net income-$14.3M-$14.3M2025
Operating income-$13.5M-$13.5M2025
Total assets$29.7M$29.7M2025
Liabilities$12.7M$12.7M2025
Equity$17.0M$17.0M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Talphera, Inc.’s revenue?
Talphera, Inc. booked $28.0k in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -51035.7% net margin.
Peers · Healthcare
enVVeno Medical Corporation40DBioasis Technologies Inc.——UMC, Inc.——Proteonomix, Inc.——Sirona Biochem Corp.——Doseology Sciences Inc.40DNeighbors
San Mateo →Key facts
CEOVincent J. Angotti
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersSan Mateo, CA
ExchangeNASDAQ: TLPH
Employees12
IPO date2011-02-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.